×
×

Agendia

MammaPrint - Agendia

MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients

MammaPrint is the first FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.

TargetPrint - Agendia

TargetPrint Provides Quantification of ER, PR and HER2 Status

TargetPrint is a microarray-based gene expression test which offers a quantitative assessment of the patient’s level of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu overexpression within her breast cancer. TargetPrint is offered in conjunction with MammaPrint to provide the physician an even more complete basis for treatment decisions. 

ColoPrint - Agendia

ColoPrint®: Enables Physicians and Patients to Embrace their Treatment Decisions with Confidence
Going Beyond Clinical Factors to Clearly Stratify ALL Stage II patients